Literature DB >> 33752802

Prolonging the integrated stress response enhances CNS remyelination in an inflammatory environment.

Yanan Chen1, Rejani B Kunjamma1, Molly Weiner1, Jonah R Chan2, Brian Popko1.   

Abstract

The inflammatory environment of demyelinated lesions in multiple sclerosis (MS) patients contributes to remyelination failure. Inflammation activates a cytoprotective pathway, the integrated stress response (ISR), but it remains unclear whether enhancing the ISR can improve remyelination in an inflammatory environment. To examine this possibility, the remyelination stage of experimental autoimmune encephalomyelitis (EAE), as well as a mouse model that incorporates cuprizone-induced demyelination along with CNS delivery of the proinflammatory cytokine IFN-γ were used here. We demonstrate that either genetic or pharmacological ISR enhancement significantly increased the number of remyelinating oligodendrocytes and remyelinated axons in the inflammatory lesions. Moreover, the combined treatment of the ISR modulator Sephin1 with the oligodendrocyte differentiation enhancing reagent bazedoxifene increased myelin thickness of remyelinated axons to pre-lesion levels. Taken together, our findings indicate that prolonging the ISR protects remyelinating oligodendrocytes and promotes remyelination in the presence of inflammation, suggesting that ISR enhancement may provide reparative benefit to MS patients.
© 2021, Chen et al.

Entities:  

Keywords:  cuprizone; integrated stress response; interferon gamma; mouse; multiple sclerosis; neuroscience; oligodendrocyte; remyelination

Year:  2021        PMID: 33752802      PMCID: PMC7987340          DOI: 10.7554/eLife.65469

Source DB:  PubMed          Journal:  Elife        ISSN: 2050-084X            Impact factor:   8.140


  51 in total

1.  The integrated stress response prevents demyelination by protecting oligodendrocytes against immune-mediated damage.

Authors:  Wensheng Lin; Samantha L Bailey; Hanson Ho; Heather P Harding; David Ron; Stephen D Miller; Brian Popko
Journal:  J Clin Invest       Date:  2007-02       Impact factor: 14.808

2.  A little stress is good: IFN-gamma, demyelination, and multiple sclerosis.

Authors:  Jason R Lees; Anne H Cross
Journal:  J Clin Invest       Date:  2007-02       Impact factor: 14.808

Review 3.  Multiple Sclerosis.

Authors:  Daniel S Reich; Claudia F Lucchinetti; Peter A Calabresi
Journal:  N Engl J Med       Date:  2018-01-11       Impact factor: 91.245

4.  Oligodendrocyte PTEN is required for myelin and axonal integrity, not remyelination.

Authors:  Emily P Harrington; Chao Zhao; Stephen P J Fancy; Sovann Kaing; Robin J M Franklin; David H Rowitch
Journal:  Ann Neurol       Date:  2010-11       Impact factor: 10.422

5.  A regenerative approach to the treatment of multiple sclerosis.

Authors:  Brian R Lawson; Peter G Schultz; Luke L Lairson; Vishal A Deshmukh; Virginie Tardif; Costas A Lyssiotis; Chelsea C Green; Bilal Kerman; Hyung Joon Kim; Krishnan Padmanabhan; Jonathan G Swoboda; Insha Ahmad; Toru Kondo; Fred H Gage; Argyrios N Theofilopoulos
Journal:  Nature       Date:  2013-10-09       Impact factor: 49.962

Review 6.  Strategies for protecting oligodendrocytes and enhancing remyelination in multiple sclerosis.

Authors:  Jane M Rodgers; Andrew P Robinson; Stephen D Miller
Journal:  Discov Med       Date:  2013-08       Impact factor: 2.970

7.  Guanabenz modulates microglia and macrophages during demyelination.

Authors:  Kaitlyn Koenig Thompson; Stella E Tsirka
Journal:  Sci Rep       Date:  2020-11-09       Impact factor: 4.379

8.  Endogenous cell repair of chronic demyelination.

Authors:  Regina C Armstrong; Tuan Q Le; Nicole C Flint; Adam C Vana; Yong-Xing Zhou
Journal:  J Neuropathol Exp Neurol       Date:  2006-03       Impact factor: 3.685

Review 9.  Glial response during cuprizone-induced de- and remyelination in the CNS: lessons learned.

Authors:  Viktoria Gudi; Stefan Gingele; Thomas Skripuletz; Martin Stangel
Journal:  Front Cell Neurosci       Date:  2014-03-13       Impact factor: 5.505

10.  Extrinsic immune cell-derived, but not intrinsic oligodendroglial factors contribute to oligodendroglial differentiation block in multiple sclerosis.

Authors:  Laura Starost; Maren Lindner; Martin Herold; Yu Kang T Xu; Hannes C A Drexler; Katharina Heß; Marc Ehrlich; Linda Ottoboni; Francesca Ruffini; Martin Stehling; Albrecht Röpke; Christian Thomas; Hans R Schöler; Jack Antel; Jürgen Winkler; Gianvito Martino; Luisa Klotz; Tanja Kuhlmann
Journal:  Acta Neuropathol       Date:  2020-09-07       Impact factor: 17.088

View more
  4 in total

Review 1.  Breaking the barriers to remyelination in multiple sclerosis.

Authors:  Marjan Gharagozloo; Riley Bannon; Peter A Calabresi
Journal:  Curr Opin Pharmacol       Date:  2022-03-04       Impact factor: 5.547

Review 2.  Beyond Myelination: Possible Roles of the Immune Proteasome in Oligodendroglial Homeostasis and Dysfunction.

Authors:  Miguel M Madeira; Zachary Hage; Stella E Tsirka
Journal:  Front Neurosci       Date:  2022-05-09       Impact factor: 5.152

3.  Treatment with IFB-088 Improves Neuropathy in CMT1A and CMT1B Mice.

Authors:  Michael E Shy; Maurizio D'Antonio; Yunhong Bai; Caroline Treins; Vera G Volpi; Cristina Scapin; Cinzia Ferri; Rosa Mastrangelo; Thierry Touvier; Francesca Florio; Francesca Bianchi; Ubaldo Del Carro; Frank F Baas; David Wang; Pierre Miniou; Philippe Guedat
Journal:  Mol Neurobiol       Date:  2022-04-30       Impact factor: 5.682

4.  Azetidine-2-Carboxylic Acid-Induced Oligodendrogliopathy: Relevance to the Pathogenesis of Multiple Sclerosis.

Authors:  Raymond A Sobel; Megan Albertelli; Julian R Hinojoza; Mary Jane Eaton; Kevin V Grimes; Edward Rubenstein
Journal:  J Neuropathol Exp Neurol       Date:  2022-05-20       Impact factor: 3.148

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.